RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets

Curr Pharm Des. 2016;22(30):4651-4657. doi: 10.2174/1381612822666160719103955.

Abstract

Background: Ischemia reperfusion injury is an important pathophysiological process in many fields such as transplantation, stroke, atherosclerosis, trauma and myocardial infarction. Recent advances in gene silencing may help to reduce ischemic effects, targeting molecules related to this pathological process.

Methods and results: Here, we review the different silencing approaches in ischemic injury, highlighting the role of co-stimulatory molecules in renal transplantation.

Conclusion: Gene silencing appears as a new strategy to prevent the inflammation and injury associated with ischemia.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / genetics
  • Acute Kidney Injury / therapy*
  • Gene Silencing
  • Humans
  • Inflammation / genetics
  • Inflammation / therapy*
  • Ischemia / genetics
  • Ischemia / therapy*
  • RNA, Messenger / genetics*
  • RNAi Therapeutics*
  • Reperfusion Injury / genetics
  • Reperfusion Injury / therapy*

Substances

  • RNA, Messenger